Biotech Co. Celldex Completes $90M Curagen Buy

Law360, New York (October 2, 2009, 5:24 PM EDT) -- Biotechnology company Celldex Therapeutics Inc. has completed its purchase of fellow cancer drug maker Curagen Corp. for more than $90 million, the companies have announced.

The two companies have signed a definitive agreement to merge, allowing Curagen to become a wholly owned subsidiary of Celldex, a joint statement released Thursday said.

Needham, Mass.-based Celldex purchased Curagen for $93.5 million, according to the companies.

Celldex and Curagen are merging to take advantage of complementary technologies they use to develop cancer drugs, a Celldex spokesman said. Both companies...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.